01—Abstract
Summary
Summary of the 8-K filed November 21, 2025. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly & Company (LLY) announced a significant addition to its Board of Directors, electing Dr. Carolyn R.
Bertozzi, a distinguished professor from Stanford University and Howard Hughes Medical Institute investigator, effective December 8, 2025. Dr. Bertozzi brings a wealth of expertise in Chemistry, Chemical & Systems Biology, and Radiology, positions that will be highly relevant to Lilly's ongoing innovation and development in the pharmaceutical sector. Her appointment is intended to bolster the Board's strategic direction, particularly through her service on the Science and Technology Committee and the Ethics and Compliance Committee.
Dr. Bertozzi's independence has been confirmed, and she will participate in the company's standard director compensation. This move signals Lilly's commitment to leveraging cutting-edge scientific knowledge at the highest governance level.
02—Key points
Key Highlights
- Eli Lilly & Company (LLY) has elected Dr. Carolyn R. Bertozzi as a new member of its Board of Directors, effective December 8, 2025.
- Dr. Bertozzi is a highly respected academic, holding professorships at Stanford University and serving as an investigator at the Howard Hughes Medical Institute.
- Her expertise spans Chemistry, Chemical & Systems Biology, and Radiology, aligning with Lilly's scientific endeavors.
- Dr. Bertozzi will contribute to the Board's strategic oversight by serving on the Science and Technology Committee and the Ethics and Compliance Committee.
- The company has affirmed Dr. Bertozzi's independence according to NYSE and company guidelines.
- Dr. Bertozzi will be subject to the company's standard director compensation plan.
- She is not involved in any undisclosed transactions with the company.
03—Questions
Frequently Asked Questions
Who is Carolyn R. Bertozzi and what is her background?
Dr. Carolyn R. Bertozzi is a renowned scientist with a Ph.D. in Chemistry. She is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology at Stanford University, and also an Investigator of the Howard Hughes Medical Institute. Her extensive background in scientific research is expected to bring valuable insights to Eli Lilly's board.
What committees will Dr. Bertozzi serve on?
Dr. Bertozzi will serve on two key committees of the Board of Directors: the Science and Technology Committee and the Ethics and Compliance Committee.
Is Dr. Bertozzi considered independent?
Yes, the Board of Directors has determined that Dr. Bertozzi is independent under the applicable standards of the New York Stock Exchange and the Company’s director independence guidelines.
Will Dr. Bertozzi be compensated differently from other directors?
No, Dr. Bertozzi will participate in the Company’s standard director compensation program, as detailed in the Company’s Definitive Proxy Statement.
04—Continue